Penumbra Inc
NYSE:PEN
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
225.54
359.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Penumbra Inc
NYSE:PEN
|
14.1B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
185.8B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
184.4B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
137.3B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
136.8B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
129.8B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
57.6B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.7B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
55B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.5B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
37.6B USD |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Penumbra Inc
Glance View
In the bustling landscape of medical technology, Penumbra Inc., founded in 2004, has etched a significant footprint by concentrating on an often-underexplored niche: therapies for neurovascular and peripheral vascular diseases. The company began its journey focusing primarily on devices to treat conditions like strokes, introducing its first product, the Penumbra System, swiftly after its inception. By innovating in thrombectomy techniques, Penumbra has provided interventionalists with the tools to effectively remove clots in the brain and restore blood flow, a crucial factor in minimizing stroke damage. The firm's pioneering spirit and commitment to addressing the unmet needs in the medical field have propelled its growth, driven by an unyielding focus on enhancing clinical outcomes for patients facing critical vascular conditions. Penumbra's success hinges not just on innovative product development but also on a comprehensive business model that centers around high-impact therapeutic solutions. It generates revenue through the sale of these specialized medical devices, primarily to hospitals and healthcare facilities across the globe. By leveraging cutting-edge technology and collaboration with healthcare professionals, Penumbra continually broadens its product portfolio, including devices for peripheral vascular interventions and embolization therapies. This focus on expanding clinical applications and adapting to emerging medical challenges ensures that Penumbra stays at the forefront of innovation, enabling it to capture a growing share of the global healthcare market. Through its focused approach, Penumbra not only makes strides in advancing medical treatments but also fortifies its position as a formidable player in the field of therapeutic medical devices.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Penumbra Inc is 13%, which is above its 3-year median of 6.9%.
Over the last 3 years, Penumbra Inc’s Operating Margin has increased from -4.7% to 13%. During this period, it reached a low of -4.7% on Sep 30, 2022 and a high of 13% on Sep 30, 2025.